We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pfizer/BioNtech’s Emergency Use Authorization (EUA) application for a COVID-19 vaccine for young children has cleared its first regulatory hurdle. Read More
Moderna released top line data yesterday from a pediatric study of its mRNA COVID-19 vaccine, which showed a half-dose of the vaccine to be safe and effective in kids ages six up to 12 years old. Read More
Last month, Walensky overrode the recommendations of the advisory committee, which supported a Pfizer/BioNTech COVID-19 booster, but not for adults at high risk of contracting the disease in the workplace. Read More
Moderna’s and Johnson & Johnson’s COVID-19 boosters, along with mixing and matching of shots, was greenlighted unanimously by scientific advisers to the Centers for Disease Control and Prevention (CDC) on Thursday, just after FDA approved the two boosters for limited populations. Read More
The White House has secured 28 million doses of the Pfizer-BioNTech pediatric COVID-19 vaccine and plans to roll out the jabs for kids age five to 11 as soon as the FDA and Centers for Disease Control and Prevention (CDC) give the go-ahead for vaccines in that age group. Read More
The FDA yesterday authorized boosters of both the Moderna and Johnson & Johnson (J&J) COVID-19 vaccines for emergency use. The agency also authorized a “mix and match” approach for emergency use that allows people to receive a booster with a different drugmaker’s product to the one they received in their initial vaccination. Read More
Since the pandemic began, the Gates Foundation has previously spent $1.9 billion to support research and development and manufacturing efforts for COVID-19 vaccines, drugs and tests. Read More
The FDA is poised to authorize booster shots of Moderna’s and Johnson & Johnson’s COVID-19 vaccines and may also allow a “mix and match” approach. Read More
For the cohort of participants needing high-flow oxygen, interferon beta-1a alone was also associated with more serious side effects, specifically, worsening respiratory responses, NIH said. Read More
AZD1222, which is not authorized in the U.S., is currently approved for use in the UK and EU, while Valneva is not yet approved for use anywhere. Read More